One of the most common questions people ask after starting Wegovy is simple: when is this supposed to work? It is a fair question, and the honest answer has two parts, because Wegovy works on two separate timelines that often get confused.
The first timeline is appetite. The second is the scale. They do not move together, and understanding the gap between them is the key to setting realistic expectations and not quitting too early.
Wegovy is the brand name for semaglutide dosed for chronic weight management, with a maintenance dose of 2.4 mg per week. It is a once-weekly injection from Novo Nordisk, the same active molecule found in Ozempic but labeled and dosed differently. If you want the full comparison, see our Wegovy vs Ozempic breakdown.
The Short Answer
Appetite suppression often begins within the first week or two on the starting 0.25 mg dose. Many people notice smaller portions, earlier fullness, and quieter cravings before the scale moves at all.
Meaningful scale weight loss usually takes several weeks to months, building gradually as the dose titrates up over the standard 16-week schedule toward the full 2.4 mg. The starter doses are designed for tolerability, not maximum effect, so early scale movement is often modest.
In the STEP-1 trial, participants on semaglutide 2.4 mg reached an average 14.9% body weight reduction at week 68 (NEJM 2021). That number reflects a named published trial, not a promise. Individual results vary.
Two Timelines: Appetite vs the Scale
This is the single most important idea in this article, so it is worth slowing down on.
Appetite is the early signal. Semaglutide acts on appetite signaling in the brain and slows gastric emptying, so food stays in the stomach longer and you feel full sooner. Those effects can show up soon after the first few doses. Many people describe it as "food noise" getting quieter, or simply forgetting to snack.
The scale is the lagging indicator. Weight loss is the downstream result of eating less over time, and it accumulates slowly. A starter dose of 0.25 mg is intentionally low to reduce nausea and other side effects while your body adjusts. It is not the dose that drives peak weight loss. That is why someone can feel a clear appetite change in week 2 and still see only a small scale change in week 4.
When people say Wegovy "is not working," they are very often measuring the wrong timeline at the wrong moment: checking the scale during the starter-dose phase, before the dose has stepped up to an effective range. Our GLP-1 results timeline guide covers this expectation gap in more detail.
A useful way to think about it: appetite is the leading indicator, and the scale is the trailing one. If your appetite has clearly changed by week 2, the medication is engaging even if the scale has not caught up. If you wait for the scale before believing it is working, you will almost always feel disappointed during the first month, because the first month is built around tolerability rather than peak effect.
The Standard 16-Week Titration Schedule
Wegovy is not started at its full strength. It steps up roughly every 4 weeks so the body can adjust and side effects stay manageable. The standard schedule looks like this:
| Weeks | Weekly dose | Purpose |
|---|---|---|
| Weeks 1 to 4 | 0.25 mg | Starter dose, build tolerance, not for max effect |
| Weeks 5 to 8 | 0.5 mg | First step up |
| Weeks 9 to 12 | 1.0 mg | Dose enters a more active range |
| Weeks 13 to 16 | 1.7 mg | Approaching maintenance |
| Week 17 onward | 2.4 mg | Maintenance dose |
Most people reach the maintenance 2.4 mg dose around month 4 to month 5. Some prescribers move slower if side effects flare, holding a dose for an extra few weeks before stepping up. A slower titration is a tolerability decision made by your clinician, not a sign that the medication is failing.
### Why the dose steps up slowly
The titration exists for one main reason: tolerability. Semaglutide slows how quickly the stomach empties, and starting too high can trigger significant nausea, vomiting, or other gastrointestinal effects. By beginning at 0.25 mg and stepping up gradually, the schedule gives your gut time to adapt at each level. The trade-off is patience: the first few weeks are not designed to maximize weight loss, they are designed to keep you on the medication long enough to reach a dose that does. People who try to rush the schedule, or who get discouraged and stop during the starter phase, frequently miss the window where the medication does its most visible work.
Week-by-Week: What to Realistically Expect
Below is a general pattern. It is not a guarantee, and where you start, how consistent you are, and your individual physiology all change the picture. Individual results vary.
### Week 1 to 2
You are on 0.25 mg. The most common early change is appetite, not weight. People often report feeling full faster, less interested in large portions, and fewer cravings. Some mild nausea or fatigue can show up as your body adjusts. The scale may not have moved meaningfully yet, and that is normal.
### Week 4
Still early. You have likely just stepped up from 0.25 mg to 0.5 mg. Appetite suppression is usually more noticeable than scale change here. Some people see a few pounds down, others see very little. Week 4 sits inside the starter phase, so it is not where peak effect happens. The best use of this window is building the habits that support the medication: adequate protein, hydration, and sleep.
### Week 8
You are around the 0.5 mg to 1.0 mg range. For many people, this is where weekly scale changes start to feel more consistent, because the dose is climbing toward a more active range. Appetite control is typically well established by now. This is also a common point to reassess habits if the scale has been flat.
### Week 12
Around the 1.0 mg dose. By the three-month mark, many people have a clearer trend line, and the combination of steady appetite control plus a higher dose tends to produce more visible cumulative results. Early plateaus can also appear here, which is normal and discussed below.
### Week 16 to 20
You are reaching or have reached the maintenance 2.4 mg dose. This is the range studied for the largest effects in the clinical trials. Weight loss generally continues to accumulate gradually over the following months rather than arriving all at once. In STEP-1, the average 14.9% reduction was measured all the way out at week 68 (NEJM 2021), which underlines that semaglutide is a long-horizon medication, not a fast one. Individual results vary.
What the Trial Data Actually Showed
It helps to anchor expectations in named published data rather than social media before-and-afters.
In the STEP-1 trial (NEJM 2021), adults with obesity or overweight taking semaglutide 2.4 mg plus lifestyle intervention lost an average of 14.9% of body weight by week 68, compared with 2.4% in the placebo group. The key word is week 68: that is well over a year. The trial did not report a fast result. It reported a large result that built up gradually over many months.
STEP-3 paired semaglutide 2.4 mg with intensive behavioral therapy, and STEP-4 examined what happened when the medication was continued versus stopped, finding that continued treatment was associated with continued weight management while stopping was associated with regain. Together these named trials describe a medication whose effect depends on reaching the full dose and staying on it, not on speed. Individual results vary, and these figures are trial averages, not Majesta outcomes or promises.
Factors That Speed Up or Slow Down Your Response
Two people can start the same week and progress very differently. Common factors include:
None of these are about willpower failure. They are practical levers that influence how the same dose behaves in different bodies.
It is also worth noting that early side effects, like nausea or fatigue, are not a measure of how well the medication will eventually work. Some people have noticeable side effects and strong results, others have minimal side effects and strong results. Side effect intensity is about tolerability, not effectiveness, and it usually eases as the body adjusts to each dose level.
What to Do If It Does Not Seem to Be Working
First, check the timeline against the dose. If you are in weeks 1 to 8, you are likely still below the most active dose range, and patience is the right move. Appetite change is the signal to watch in this window, not the scale.
If you have reached the full 2.4 mg dose, given it adequate time, and still see no appetite change or progress, that is a conversation to have with your prescriber rather than a reason to stop or self-adjust. A clinician can review adherence, dose, side effects, other medications, and habits, and decide whether a change is appropriate. Stopping abruptly or changing your own dose tends to create more problems than it solves.
A few practical checkpoints before deciding the medication is not working:
If those checkpoints are all in order at full dose and progress has genuinely stalled, that is the right moment for a clinical review.
Plateaus Are Normal
Weight loss on any GLP-1 is rarely a straight line. It is common to lose steadily for a stretch, then stall for a week or several weeks, then resume. A plateau is not the same as the medication failing. As you lose weight, your body needs fewer calories, so the same intake that once created a deficit may no longer do so. Reaching the next dose step, revisiting protein and portion habits, and protecting sleep are the usual first moves. Persistent plateaus are worth raising with your prescriber.
Early plateaus in the first few months are especially common right around dose transitions, and they often resolve on their own as the next dose step takes hold. A plateau that lasts many weeks at the full maintenance dose is a different situation and is worth a conversation with your clinician about habits, dose, and whether a maintenance strategy needs adjusting.
How to Track Progress Without Obsessing Over the Scale
Because appetite leads and the scale lags, the scale alone is a poor early scorecard. A more complete picture in the first couple of months includes:
Weighing once a week under consistent conditions, rather than daily, tends to give a calmer and more accurate trend line. Daily weigh-ins capture normal water-weight noise that has nothing to do with fat loss and can make a working medication feel like it is doing nothing. Individual results vary.
A Note on Compounded Semaglutide
Some patients access semaglutide through compounded formulations prescribed by US-licensed physicians, often on a similar step-up titration schedule. The general pattern of early appetite change followed by gradual scale movement is comparable, because it is the same active ingredient, though exact dosing is individualized by the prescriber. Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient is FDA-registered. You can read more in our compounded semaglutide guide, and see current options and pricing on our pricing page. Individual results vary.
The Bottom Line
Wegovy usually starts working on appetite within the first week or two, and on the scale over several weeks to months as the dose climbs through the 16-week titration toward 2.4 mg. The starter doses are built for tolerability, not maximum effect, so judging the medication by week 4 on the scale sets the wrong expectation. The clinical trials describe a slow, cumulative result measured over many months, not a fast one. Individual results vary.
If you are early, watch your appetite, build supportive habits, and let the titration do its work. If you are at full dose and stalled, talk with your prescriber.
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider. Individual results vary. The information provided is not a substitute for professional medical guidance.
Frequently Asked Questions
How long does Wegovy take to work?
Wegovy works on two different timelines. Appetite suppression often begins within the first week or two on the starting 0.25 mg dose, when many people notice smaller portions and fewer cravings. Meaningful movement on the scale usually takes longer, building over several weeks to months as the dose titrates up through the standard 16-week schedule toward the full 2.4 mg. In the STEP-1 trial (NEJM 2021), participants reached an average 14.9% body weight reduction at week 68. Individual results vary.
When does Wegovy start working for appetite?
Many people feel reduced appetite within the first one to two weeks on the 0.25 mg starting dose, because semaglutide begins acting on appetite signaling soon after the first few doses. The effect typically strengthens as the dose increases. Appetite change is usually the first sign the medication is doing something, well before the scale reflects it. Individual results vary, and some people notice the shift sooner or later than others.
How fast does Wegovy work on the scale?
Scale weight loss is gradual and tied to the titration schedule. The first 0.25 mg dose is a starter dose intended to reduce side effects, not to drive maximum weight loss, so early scale movement is often modest. Most people see steadier weekly changes once they reach the higher 1.0 mg, 1.7 mg, and 2.4 mg doses over the first few months. The STEP-1 trial measured its average 14.9% reduction at week 68 (NEJM 2021). Individual results vary.
What should I expect at week 4 on Wegovy?
By week 4, most people are still on a starting dose (0.25 mg for the first 4 weeks, then 0.5 mg). The most common change at this point is reduced appetite and earlier fullness rather than a large drop on the scale. Some scale movement may appear, but week 4 is early in the titration and not where peak effect happens. Use this window to build the eating, sleep, and hydration habits that support results. Individual results vary.
Why is Wegovy not working for me yet?
If you are early in titration, the medication may simply not be at an effective dose yet, since the starter doses are designed for tolerability rather than maximum effect. Other factors that influence response include dose adherence, diet quality, protein intake, sleep, activity, starting weight, and other medications. If you have reached the full 2.4 mg dose and given it adequate time without appetite change or progress, talk with your prescriber rather than stopping or adjusting on your own. Individual results vary.
How long until Wegovy reaches its full dose?
The standard Wegovy titration is a 16-week schedule that steps up roughly every 4 weeks: 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg. So most people reach the maintenance 2.4 mg dose around month 4 to month 5, assuming the steps are tolerated. Some prescribers slow the schedule to manage side effects, which can push the full-dose date later. The slower pace is a tolerability decision, not a sign of failure.
Is compounded semaglutide timeline the same as Wegovy?
Compounded semaglutide uses the same active ingredient as Wegovy and is typically titrated on a similar step-up schedule under physician supervision, so the general pattern of early appetite change followed by gradual scale movement is comparable. Exact dosing is individualized by the prescriber. Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient is FDA-registered. Individual results vary.
All Majesta Health medical content is clinically reviewed before publication by US-licensed physicians affiliated with our clinical infrastructure partner, MD Integrations (MDI). Reviewers hold active state medical licenses, are board-certified in primary care or obesity medicine, and specialize in GLP-1 receptor agonist therapy for chronic weight management. MDI is LegitScript certified and SOC 2 Type II accredited.
- US-licensed physicians affiliated with our clinical partner MD Integrations (LegitScript certified, HIPAA, SOC 2 Type II, ISO certified)
- Board-certified in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across all 50 US states and DC through the MD Integrations Medical Services Organization
- Dispensing pharmacy partner: Belmar Pharma Solutions (LegitScript certified, NABP accredited, 503A and 503B compounding)